This guidance updates and replaces NICE technology appraisal guidance 3 (published in May 2000).
This guidance has been partially updated by NICE technology appraisal guidance 91 (published May 2005).
Recommendations 1.3, 1.4 and 1.5 of TA55 on re-challenge therapy and the second-line treatment of advanced ovarian cancer have been replaced. The recommendations for first-line treatment still stand.
For further information regarding this, please see the 'Review update on the use of paclitaxel (1st line only) in the treatment of ovarian cancer' document under 'Background information'.